Next-Generation Nanovector Systems for Personalized Medicine

The next-generation nanovector system enables targeted delivery of multiple active substances, leveraging computational frameworks and personalized nanoparticle libraries to revolutionize disease treatment.

The original patent disclosed nanovectors for delivering active substances, but was limited to single-substance delivery and lacked personalized targeting capabilities. The new inventive concept addresses these limitations by introducing a modular, computational framework-driven approach to nanovector design, enabling tailored therapy for individual patients.

The next-generation nanovector system comprises a plurality of polysiloxane-based nanoparticles with distinct surface chemistries, each optimized for a specific active substance. A computational framework predicts optimal nanoparticle-substance combinations, and a method for generating personalized nanovector libraries involves analyzing a patient's genetic profile and identifying target active substances. The system also includes a nanovector-based therapeutic platform with stimuli-responsive elements and modular designs for adaptable therapy.

The new claims introduce a paradigm shift in nanovector technology by enabling multi-substance delivery, personalized targeting, and modular design. The computational framework and nanoparticle library generation method are novel and non-obvious, providing a significant inventive step beyond the original patent.

Alternative embodiments could include varying nanoparticle core materials, different targeting moieties, or incorporation of additional stimuli-responsive elements. Variations could also involve adapting the computational framework for different disease types or patient populations.

The next-generation nanovector system has significant commercial potential in the personalized medicine market, particularly in the treatment of complex diseases such as cancer and genetic disorders. Target industries include pharmaceutical companies, biotechnology firms, and medical research institutions.